Basit öğe kaydını göster

dc.contributor.authorOZSUT, Halit
dc.contributor.authorCAGATAY, Yonca
dc.contributor.authorCALANGU, S
dc.contributor.authorCagatay, Arif Atahan
dc.contributor.authorAKSOZ, Selçuk
dc.contributor.authorCALISKAN, Y
dc.contributor.authorGULEC, L
dc.contributor.authorKUCUKOGLU, S
dc.contributor.authorBERK, H
dc.contributor.authorERAKSOY, H
dc.date.accessioned2021-03-04T18:54:13Z
dc.date.available2021-03-04T18:54:13Z
dc.identifier.citationCagatay A. A. , CALISKAN Y., AKSOZ S., GULEC L., KUCUKOGLU S., CAGATAY Y., BERK H., OZSUT H., ERAKSOY H., CALANGU S., "Extrapulmonary tuberculosis in immunocompetent adults", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, cilt.36, ss.799-806, 2004
dc.identifier.issn0036-5548
dc.identifier.othervv_1032021
dc.identifier.otherav_8d1dc491-b348-4410-b52d-4813d7b697e1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/95409
dc.identifier.urihttps://doi.org/10.1080/00365540410025339
dc.description.abstractTuberculosis continues to be a significant cause of morbidity and mortality. Although tuberculosis usually attacks the lungs, other organs can also be affected, leading to extrapulmonary tuberculosis (EPT) or disseminated tuberculosis. This study retrospectively analysed the incidence, clinical sites and risk factors for EPT in 252 patients with EPT between 1 January 1991 and 30 June 2003. EPT was defined as clinical, laboratory, imaging, and/or histopathological evidence of mycobacterial infection in a site other than hilar lymph nodes or lung parenchyma. In our study group, tuberculous lymphadenitis (36.5%) was found to be the most common clinical presentation of EPT. 119 ( 47.2%) patients developed the severe form of EPT, according to the WHO report, and 133 (52.8%) patients developed the less severe form. A case history of pulmonary tuberculosis was found to be a risk factor for the development of EPT (p < 0.05). The study showed that EPT is still a public health problem. These findings suggested that pulmonary tuberculosis may play a critical role in the development of EPT. 12-month therapy may be chosen in patients with EPT considering acceptable adverse effects without relapses.
dc.language.isoeng
dc.subjectİmmünoloji
dc.subjectTemel Bilimler
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.titleExtrapulmonary tuberculosis in immunocompetent adults
dc.typeMakale
dc.relation.journalSCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume36
dc.identifier.startpage799
dc.identifier.endpage806
dc.contributor.firstauthorID67615


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster